European “Substances Of Very High Concern” List Published; Now What?
This article was originally published in The Gray Sheet
Executive Summary
U.S. device manufacturers are pushing for more guidance on ways to comply with new European requirements for devices containing chemicals classified as "substances of very high concern.
You may also be interested in...
FDA Task Force Takes Hard Look At Leachable Chemical In Medical Products
FDA is stepping up research into a chemical used in some plastics, including medical devices, in the wake of a recent National Institutes of Health brief outlining related safety concerns
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.